In March 2026, Denali Therapeutics received FDA accelerated approval for AVLAYAH, the first blood-brain-barrier-crossing biologic enzyme replacement therapy for neurologic manifestations of Hunter ...

United Therapeutics surged more than 12% in pre-market trading on March 30 after positive TETON-1 trial data triggered price ...

This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains ...

If you are wondering whether CRISPR Therapeutics at around US$45.75 is a bargain or a value trap, the answer depends on how you look at its valuation. The stock has returned 23.7% over the last year, ...